Submission Deadline 03/10/2027
Fiscal Capacity $50,135,013
| Opportunity Number | RFA-DK-27-108 |
|---|---|
| Agency | HHS-NIH11 |
| Application Deadline | 03/10/2027 |
| Award Amount | $50,135,013 |
| Status | Posted |
| Sector | Health |
| Cost Sharing | Not Required |
Fiscal Parameters & Taxonomy
Authority HHS-NIH11
Status Posted
Who Can Apply
Special district governments County governments Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public housing authorities/Indian housing authorities Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) City or township governments State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Eligibility Intelligence
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Program Description
The NIH Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) was created to improve research on type 1 diabetes (T1D) and cardiovascular disease (CVD). Cardiovascular complications remain the top cause of death among people with T1D and greatly shorten lifespan. The mechanisms underlying atherosclerosis, cardiomyopathy, endothelial dysfunction, and cardiac autonomic neuropathy in T1D remain poorly understood. While managing traditional risk factors—such as high blood glucose, high blood pressure, and elevated cholesterol lower cardiovascular risk, a significant residual risk remains even with optimal control. In addition to atherosclerosis, both diastolic and systolic diabetic cardiomyopathy play a major role in morbidity and mortality among these patients. Currently, no therapies are specifically approved to prevent or treat these common and severe cardiovascular issues in T1D. The purpose of this NOFO is to promote collaborative and interdisciplinary research aimed at enhancing the understanding of the development of CVD in individuals with T1D and the differences with CVD in T1D by continuing the efforts of the CaRe-T1D consortium.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
CFDA Programs
93.233 National Center on Sleep Disorders Research
93.837 Cardiovascular Diseases Research
93.838 Lung Diseases Research
93.839 Blood Diseases and Resources Research
93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
Agency Contact
Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK_DEM@nih.gov
✉ NIDDK_DEM@nih.gov📞 301-402-2541
Related Intelligence Guides
In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.